EGFR and breast carcinoma: To summarize all that we have gathered, the aforementioned data supported a conclusion that EVs-miR-182-5p may function as a driver of breast cancer progression and suggested a molecular mechanism that miR-182-5p bound to CMTM7 to activate the EGFR/AKT signaling pathway in this process (Additional file 4: Fig. S3).